August 28, 2013 — Effective Oct. 1, Cook Medical’s Zilver PTX drug-eluting peripheral stent qualifies for new-technology add-on payments under Medicare’s hospital inpatient prospective payment system.

According to Millennium Research Group (MRG), efforts to streamline the regulatory approval process in Japan have resulted in the recent entry of numerous devices in the Japanese peripheral vascular (PV) device market, and more products, such as drug-coated balloons and infrapopliteal stents, are expected to enter in the next few years.

 

 

Experts have found that radiation dosage can have serious complications for patients with cancer. Cancer patients who receive chest radiation should be evaluated for heart disease before beginning radiation, and every five to 10 years afterward, according to the American Society of Echocardiography (ASE) and the European Assn. of Cardiovascular Imaging (EACVI) of the European Society of Cardiology (ESC). This expert consensus statement on the use of imaging to detect radiation-induced heart disease (RIHD) will be published in the September issue of the Journal of the American Society of Echocardiography (JASE). The writing group was co-chaired by Vuyisile Nkomo, M.D., an echocardiographer from the renowned Mayo Clinic in Rochester, Minn.

AliveCor Inc. released a new AliveECG App for its Heart Monitor that features an Enhanced Filter, a noise cancelling technology that improves the visual output of the ECG. The AliveCor Heart Monitor is a mobile device-based ECG monitor for the iPhone 4, 4S and 5 that is used to record, display, store and transfer single-channel electrocardiogram (ECG) rhythms.

Edwards Lifesciences Corp. announced that Japan's Central Social Insurance Medical Council (Chuikyo) has approved the recommendation by the Japanese Ministry of Health, Labor and Welfare's (MHLW) expert review panel to provide reimbursement for the Edwards Sapien XT transcatheter aortic heart valve. The reimbursement is scheduled to go into effect on Oct. 1.

JenaValve Technology Inc. has successfully completed the first two implantations of its second-generation transapical JenaValve transcatheter aortic valve implantation (TAVI) system in Canada. These are also the first two implantations of the second-generation transapical JenaValve TAVI system outside of Europe.

 

Adopting an approach that encourages continued progress while simultaneously acknowledging short-term obstacles, the Healthcare Information and Management Systems Society (HIMSS) recommends launching Stage 2 Meaningful Use on-schedule and extending Year 1 of the Meaningful Use Stage 2 attestation period through April 2015 and June 2015 for eligible hospitals (EHs) and eligible professionals (EPs), respectively.  This would encompass 18 months in which EHs and EPs can attest to Meaningful Use requirements for one quarter.

Boston Scientific Corp. has completed enrollment in the SuperNOVA trial – a global, single arm, prospective, multicenter clinical trial evaluating the long-term (12-month) safety and effectiveness of the Innova Self-Expanding Stent System (Innova Stent System). This stent system is designed for treating patients with a narrowing or blockage of the arteries above the knee, often associated with peripheral artery disease (PAD).

 
Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now